DIRECTOR DEALINGS: Akers Biosciences Chief Executive Buys First Shares

Thu, 26th May 2016 16:27

LONDON (Alliance News) - Akers Biosciences Inc on Thursday said Chief Executive John Gormally on Tuesday made five separate share purchases, and now holds 2,500 shares in the company.

Gormally purchased 69 shares at USD2.19 per share, 1,000 shares at USD2.20 per share, 100 shares at USD2.23 per share, 200 shares at USD2.24 per share and 1,131 shares at USD2.25 shares.

Following the transactions, Gormally holds 2,500 shares, or a 0.05% stake, in Akers Biosciences.

Shares in Akers Biosciences were untraded on Thursday, having last traded at 131.00 pence.

By Hannah Boland; hannahboland@alliancenews.com; @Hannaheboland

Related Shares

More News

8 Oct 2018 13:10

Akers Biosciences appoints chief executive after settling legal battle

(Sharecast News) - Akers Biosciences appointed Howard Yeaton as chief executive on Monday as the company reached a settlement in its legal dispute wit...

15 Aug 2018 08:04

Akers Biosciences profits hit over antigen difficulties

(Sharecast News) - Akers Biosciences' losses burgeoned as second-quarter revenues were cut in half after softer sales of its flagship Heparin rapid as...

3 Apr 2018 13:45

Akers Biosciences 2017 Revenue Rises But Loss Widens On Higher Costs

LONDON (Alliance News) - Akers Biosciences Inc on Tuesday said revenue grew in 2017, but its loss widened due to increased costs across the business.T...

16 Mar 2018 18:11

Akers Biosciences Nets USD49,000 From Warrants Exercise (ALLISS)

LONDON (Alliance News) - Akers Biosciences Inc, a developer of health screening and testing products, said Friday that it has netted USD48,750 from wa...

16 Feb 2017 08:44

Akers Biosciences gains US patent for disposable cartridge

(ShareCast News) - Akers Biosciences, a developer of rapid health information technologies, has been granted a US patent for its wellness disposable m...